No Detail Found!

FOXQ1 Suppressing Apoptosis in Colorectal Cancer Cells by P53 Deacetylation

Author(s)
Guisong Yang Department of Gastrointestinal Surgery, General Surgery Centre, Qingdao Municipal Hospital, Affiliated to Qingdao Medical College, Qingdao University,Qingdao,China
Huanjie Chen Department of Gastrointestinal Surgery, General Surgery Centre, Qingdao Municipal Hospital, Affiliated to Qingdao Medical College, Qingdao University,Qingdao,China
Xiaolei Ma Department of Gastrointestinal Surgery, General Surgery Centre, Qingdao Municipal Hospital, Affiliated to Qingdao Medical College, Qingdao University,Qingdao,China
Fugang Wang Department of Gastrointestinal Surgery, General Surgery Centre, Qingdao Municipal Hospital, Affiliated to Qingdao Medical College, Qingdao University,Qingdao,China
Guiliang Ma Department of Gastrointestinal Surgery, General Surgery Centre, Qingdao Municipal Hospital, Affiliated to Qingdao Medical College, Qingdao University,Qingdao,China
Hong Qi Department of Gastrointestinal Surgery, General Surgery Centre, Qingdao Municipal Hospital, Affiliated to Qingdao Medical College, Qingdao University,Qingdao,China
Abstract
To investigate the impact of Forkhead box Q1 (FOXQ1) expression on platinum-based chemoresistance in colorectal cancer (CRC) cells, and to examine the regulatory function of FOXQ1 on Sirtuin 1 (SIRT1) protein expression and P53 protein deacetylation levels during the DNA damage response (DDR). Study Design: An experimental study. Place and Duration of the Study: Second Department of Gastrointestinal Surgery, General Surgery Centre, Qingdao Municipal Hospital, A liated to Qingdao Medical College, Qingdao University, Qingdao, China, from October 2023 to December 2024. Methodology: Gene expression levels of FOXQ1 in CRC cells and SW620 cells treated with cisplatin (CDDP) were evaluated using quantitative real-time polymerase chain reaction (qRT-PCR). The t-test was used to compare the gene expression levels between the two groups. Three gene-edited SW620 cell models were established: FOXQ1 overexpression (oe-FOXQ1), FOXQ1 RNA interference (shFOXQ1), and a negative control (NC). CCK-8 assays measured CDDP's half-inhibitory concentration (IC50), while ow cytometry, calcein-AM/PI staining, and colony formation evaluated cell apoptosis and survival. Western blot analysed SIRT1 and acetylated p53, and the SIRT1 inhibitor (S)-Selisistat explored FOXQ1-related pathways. Results: FOXQ1 was highly expressed in CRC. CDDP treatment further increased its expression in SW620 cells.FOXQ1 overexpression enhanced CDDP resistance, elevated SIRT1 levels, and promoted P53 deacetylation. (S)-Selisistat reversed P53 deacetylation and reduced CDDP resistance in oe-FOXQ1 cells. Conclusion: FOXQ1 promotes chemoresistance in CRC by upregulating SIRT1 expression and promoting P53 deacetylation, thereby inhibiting apoptosis triggered by DDR.
Publication Details
Page(s) 722-729
Published Journal: Journal of the College of Physicians and Surgeons Pakistan, Volume: 35, Issue: 06, Year: 2025

Request the full text from PASTIC

Keywords
Apoptosis, colorectal cancer, Forkhead Box Q1, Sirtuin 1, P53 Acetylation
References
Ladabaum U,Dominitz JA,Kahi C,Schoen RE .2019 .Strategies for colorectal cancer screening. Gastroenterology, 06(2) : 418-32.
Kong Y,Hong L,Xu X .2020 .Potentially resectable mCRC-treated with cetuximab combined with chemotherapy. J Coll Physicians Surg Pak, 11(11) : 1206-12.
Wang P,Lv C,Zhang T,Liu J,Yang J,Guan F .2017 .FOXQ1 regulates senescence-associated in ammationvia activation of SIRT1 expression. Cell Death Dis, 340(7) : .
Li Y,Zhang Y,Yao Z,Li S,Yin Z,Xu M. .2016 .Forkhead box Q1: A key player in the pathogenesis of tumours (review). Int J Oncol, 3517(1) : 51-8.
Wu C,Zheng C,Chen S,He Z,Hua H,Sun C .2023 .FOXQ1 promotes pancreatic cancer cell proliferation, tumour stemness, invasion and metastasis through regulation of LDHAmediated aerobic glycolysis. Cell Death Dis, 10(10) : 699.
Zhang H,Meng F,Liu G,Zhang B,Zhu J,Wu F .2011 .Forkhead transcription factor FOXQ1 promotes epithelial-mesenchymal transition and breast cancer metastasis. Cancer Res, 10(4) : 0008-5472.
Kaneda H,Arao T,Tanaka K,Tamura D,Aomatsu K,Kudo K .2010 .FOXQ1 is overexpressed in colorectal cancer and enhances tumourigenicity and tumour growth. Cancer Res, 09(5) : 0008-5472.
Yang M,Liu Q,Dai M,Peng R,Li X,Zuo W .2022 .FOXQ1-mediated SIRT1 upregulation enhances stemness and radioresistance of colorectal cancer cells and restores intestinal microbiota function by promoting beta-catenin nuclear translocation. J Exp Clin Cancer Res, 10(1) : 70.
Mitchell AV,Wu L,Block CJ,Zhang M,Hackett J,Craig DB .2022 .FOXQ1 recruits the MLL complex to activate transcription of EMT and promote breast cancer metastasis. Nat Commun, 10(1) : 6548.
Hong X,Liu N,Liang Y,He Q,Yang X,Lei Y .2020 .Circular RNA CRIM1 functions as a ceRNA to promote nasopharyngeal carcinoma metastasis and docetaxel chemoresistance through upregulating FOXQ1. Mol Cancer, 10(1) : 33.
Fan J,Bertino JR .1999 .Modulation of cisplatinum cytotoxicity by p53: E ect of p53-mediated apoptosis and DNA repair. Mol Pharmacol, 10(5) : 966-72.
Jung MS,Jin DH,Chae HD,Kang S,Kim SC,Bang YJ .2004 .Bcl-xL and E1B-19K proteins inhibit p53-induced irreversible growth arrest and senescence by preventing reactive oxygen species-dependent p38 activation. J Biol Chem, 10(17) : 17765-71.
Levine AJ .1997 .the cellular gatekeeper for growth and division. Cell, 8674(00) : 81871-1.
Vaddavalli PL,Schumacher B. .2022 .The p53 network: Cellular and systemic DNA damage responses in cancer and aging. Trends Genet, 02(6) : 598-612.
Rodier F,Campisi J,Bhaumik D .2007 .Two faces of p53: aging and tumour suppression. Nucleic Acids Res, 10(22) : 7475-84.
Lu D,Faizi M,Drown B,Simerzin A,Francois J,Bradshaw G .2024 .Temporal regulation of gene expression through integration of p53 dynamics and modi cationsS. ci Adv, 10(43) : .
Sturmlechner I,Zhang C,Sine CC,van Deursen EJ,Jeganathan KB,Hamada N .2021 .p21 produces a bioactive secretome that places stressed cells under immunosurveillance. Science, 10(6567) : .
Ito A,Lai CH,Zhao X,Saito S,Hamilton MH,Appella E .2001 .p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J, 10(6) : 1331-40.
Sakaguchi K,Herrera JE,Saito S,Miki T,Bustin M,Vassilev A .1998 .DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev, 10(18) : 2831-41.
Solomon JM,Pasupuleti R,Xu L,McDonagh T,Curtis R,DiStefano PS .2006 .Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. / MCB.26.1, 10(1) : 28-38.
Tang Y,Ju W,Liu Y,Deng Q. .2024 .The role of SIRT1 in autophagy and drug resistance: Unveiling new targets and potential biomarkers in cancer therapy. Front Pharmacol, 1469830 : 1469830.
Dong W,Zhang K,Wang X,Li J,Zou H,Yuan Y .2024 .SIRT1 alleviates Cd nephrotoxicity through NF-kappaB/p65 deacetylation-mediated pyroptosis in rat renal tubular epithelial cells. Sci Total Environ, 172392 : 172392.
0

Citations

0

Downloads

25

Views